Table 2.
Clinical characteristics at initiation of 7 bDMARDs and tofacitinib (bDMARDs-switched cases)
| Variable | ABT (n = 273) | ADA (n = 162) | CZP (n = 91) | ETN (n = 240) | GLM (n = 250) | IFX (n = 74) | TCZ (n = 487) | TOF (n = 101) |
|---|---|---|---|---|---|---|---|---|
| Age (years) | 61.5 ± 13.2 | 55.4 ± 14.8 | 54.1 ± 15.4 | 55.5 ± 15.7 | 60.5 ± 14.6 | 53.5 ± 12.6 | 58.1 ± 14.1 | 59.7 ± 13.6 |
| Female sex (%) | 81.3 | 87.7 | 85.7 | 82.1 | 88.0 | 79.5 | 82.5 | 77.2 |
| Disease duration (years) | 11.2 ± 9.3 | 9.7 ± 9.0 | 9.9 ± 9.0 | 9.4 ± 8.1 | 12.0 ± 10.2 | 10.9 ± 16.0 | 10.0 ± 8.9 | 11.0 ± 8.6 |
| RF positivity (%) | 77.8 | 78.2 | 77.2 | 75.6 | 78.1 | 72.7 | 79.9 | 80.0 |
| ACPA positivity (%) | 84.4 | 80.9 | 84.8 | 86.5 | 82.9 | 82.4 | 83.3 | 73.3 |
| DAS28-ESR | 4.3 ± 1.3 | 3.9 ± 1.1 | 4.4 ± 1.5 | 4.1 ± 1.4 | 4.0 ± 1.4 | 4.0 ± 1.6 | 4.4 ± 1.4 | 4.3 ± 1.3 |
| CDAI | 14.7 ± 9.5 | 11.9 ± 8.8 | 16.3 ± 10.8 | 13.7 ± 10.0 | 14.6 ± 10.2 | 18.9 ± 13.0 | 16.3 ± 10.3 | 19.3 ± 11.3 |
| HAQ-DI | 1.1 ± 0.8 | 0.8 ± 0.7 | 1.2 ± 0.9 | 0.9 ± 0.8 | 1.1 ± 0.8 | 1.0 ± 1.0 | 1.2 ± 0.8 | 1.0 ± 0.8 |
| PSL usage (%) | 55.1 | 44.1 | 40.7 | 47.0 | 46.0 | 42.5 | 52.2 | 54.5 |
| PSL dose (mg/day) | 6.4 ± 4.1 | 5.9 ± 4.3 | 4.9 ± 2.9 | 5.6 ± 3.8 | 5.1 ± 3.5 | 5.6 ± 3.1 | 6.1 ± 3.9 | 4.1 ± 3.1 |
| MTX usage (%) | 47.8 | 57.1 | 62.6 | 50.0 | 66.1 | 100.0 | 54.9 | 51.5 |
| MTX dose (mg/week) | 8.4 ± 3.0 | 8.0 ± 2.9 | 8.4 ± 3.1 | 8.3 ± 2.7 | 8.0 ± 3.1 | 8.7 ± 2.8 | 8.4 ± 3.1 | 9.0 ± 3.3 |
| Starting date 2001–2009 (%) | 0.0 | 25.3 | 0.0 | 27.5 | 0.0 | 20.3 | 10.9 | 0.0 |
| Starting date 2010–2013 (%) | 43.2 | 49.4 | 26.4 | 37.5 | 48.8 | 51.4 | 45.8 | 2.0 |
| Starting date 2014–2019 (%) | 56.8 | 25.3 | 73.6 | 35.0 | 51.2 | 28.4 | 43.3 | 98.0 |
| 2nd bio or TOF (%) | 54.6 | 75.9 | 41.8 | 74.6 | 58.8 | 70.3 | 57.3 | 31.7 |
| ≥ 3rd bio or TOF (%) | 45.4 | 24.1 | 58.2 | 25.4 | 41.2 | 29.7 | 42.7 | 68.3 |
Values are mean ± standard deviation or percentages. bDMARDs biological disease-modifying antirheumatic drugs, ABT abatacept, ADA adalimumab, CZP certolizumab pegol, ETN etanercept, GLM golimumab, IFX infliximab, TCZ tocilizumab, TOF tofacitinib, RF rheumatoid factor, ACPA anti-cyclic citrullinated peptide antibody, DAS28-ESR Disease Activity Score in 28 joints using erythrocyte sedimentation rate, CDAI clinical disease activity index, HAQ-DI Health Assessment Questionnaire disability index, PSL prednisolone, MTX methotrexate, bio biologic agent